Tozinameran is mRNA encoding full length of spike protein analog of SARS-CoV-2
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
Pathway
ko03230
Viral genome structure
ko05171
Coronavirus disease - COVID-19
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J07 VACCINES
J07B VIRAL VACCINES
J07BX Other viral vaccines
J07BX03 Covid-19 vaccines
D11971 Tozinameran (JAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
63 Biological preparations
631 Vaccines
6313 Viral vaccines
D11971 Tozinameran (JAN)
Drug groups [BR:br08330]
Antiviral
DG03172 COVID-19 vaccine
D11971 Tozinameran
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11971
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11971
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11971
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11971